RapaLink-1

RapaLink-1 is a third-generation, bi-steric, small-molecule inhibitor of the mammalian target of rapamycin (mTOR). It is a bivalent compound created by chemically linking rapamycin (a first-generation allosteric mTORC1 inhibitor) with an ATP-competitive mTOR kinase inhibitor (MLN0128), resulting in a molecule designed to bind both the FKBP12-rapamycin binding domain and the kinase domain of mTOR. This bitopic engagement increases potency, overcomes resistance mutations to earlier mTOR inhibitors, and inhibits both mTORC1 and mTORC2 complexes in cancer models. RapaLink-1 has shown superior efficacy compared to rapamycin or second-generation mTOR inhibitors in preclinical models of glioblastoma, renal cell carcinoma, and prostate cancer. It crosses the blood-brain barrier and can induce tumor regression and cell cycle arrest at G0/G1, while efficiently blocking phosphorylation of key mTOR effectors such as 4EBP1 and S6. It has also demonstrated the ability to overcome resistance to mTORC1-specific inhibitors and target mTOR pathway mutations common in various cancers. RapaLink-1 is a research compound and has not been approved for clinical use as of the latest data.

Other names

RapaLink-1RapaLink1RapaLink 1